NCT07354282Completed
Real World Evidence of Tivozanib as First-line Treatment for Metastatic Clear Cell Renal Cell Carcinoma
Retrospective, Multicenter, Real-world Observational Study of Tivozanib as First-line Treatment for Metastatic Clear Cell Renal Cell Carcinoma.
Source: ClinicalTrials.gov · Last updated 21 Jan 2026
Brief summary (registry, in English)
The SOGUG-TIVOREAL study is a retrospective observational study with medications. This study is based on the retrospective collection of data from patients who have been treated with Tivozanib as first-line therapy between 03/01/2019 and 08/31/2024 for metastatic renal cell carcinoma (mRCC).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 200 (actual)
- First submitted
- 24 Sept 2025
- Start date
- May 2025
- Primary completion date
- Aug 2025
- Lead sponsor
- Spanish Oncology Genito-Urinary Group
- Diseases
- Kidney cancer
- NCT number
- NCT07354282
What you commit to
- Study type: Observational
- Participants enrolled: 200
- From May 2025 to the primary completion date, Aug 2025
- 14 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \- Patients previously treated at another center who were later referred to one of the participating centers. In this case, the patient will be included in the center where the treatment was initiated.
Other
- \- Explicit objection by the subject or their legal representative to participate in the study.
Who the study is looking for
- \- Patients ≥ 18 years old.
- \- Who have signed the informed consent form, except for patients who were deceased at the time of inclusion.
- \- Histological diagnosis of stage IV clear cell renal carcinoma.
- \- Who started treatment with Tivozanib as first-line therapy between March 1, 2019, and August 31, 2024.
- \- Who received treatment at the participating center.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (14)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Vall de Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Unknown status |
| Hospital de Burgos Coordinator of this site? Confirm its status | Burgos | Spain | Unknown status |
| Hospital Reina Sofia Coordinator of this site? Confirm its status | Córdoba | Spain | Unknown status |
| Hospital Severo Ochoa Coordinator of this site? Confirm its status | Leganés | Spain | Unknown status |
| Hospital de León Coordinator of this site? Confirm its status | León | Spain | Unknown status |
| Institut Català d'Oncologia (ICO) de L'Hospitalet de Llobregat Coordinator of this site? Confirm its status | L'Hospitalet de Llobregat | Spain | Unknown status |
| Hospital Lucus Augusti Coordinator of this site? Confirm its status | Lugo | Spain | Unknown status |
| Hospital Gregorio Marañon Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
| Fundación Jiménez Díaz Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
| Hospital Puerta de Hierro Coordinator of this site? Confirm its status | Majadahonda | Spain | Unknown status |
| Hospital Virgen de la Victoria Coordinator of this site? Confirm its status | Málaga | Spain | Unknown status |
| Hospital Parc Tauli Coordinator of this site? Confirm its status | Sabadell | Spain | Unknown status |
| Hospital Virgen Del Rocio Coordinator of this site? Confirm its status | Seville | Spain | Unknown status |
| Instituto Valenciano de Oncología (IVO) Coordinator of this site? Confirm its status | Valencia | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.